Mirtazapina Krka (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Krka, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It treats major depressive disorder in adult patients, helping to improve mood, sleep, and appetite.

GNH USA supplies Mirtazapina Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required and comprehensive regulatory support throughout.

Mirtazapina Krka, as a NaSSA antidepressant, is indicated for conditions within the major depressive disorder spectrum.

- Major depressive disorder: reduces depressive symptoms, improves mood, sleep quality, and appetite in adult patients. - Depressive episodes with insomnia: helps restore normal sleep patterns while alleviating depressive mood. - Depressive symptoms with anxiety: lessens anxiety and tension associated with depressive states.

Mirtazapina Krka may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe hypersensitivity reactions such as rash or angioedema - Suicidal thoughts or worsening depression

When prescribing Mirtazapina Krka, clinicians should consider several safety measures.

- Assess hepatic function: evaluate liver enzymes before initiating therapy. - Monitor body weight: watch for rapid weight gain and adjust nutrition as needed. - Screen for suicidal ideation: especially during the first weeks of treatment. - Use caution in elderly patients: increased risk of sedation and falls. - Avoid abrupt discontinuation: taper the dose under medical supervision to prevent withdrawal. - Store at room temperature: keep in the original container, protect from moisture and light.

Mirtazapina Krka interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other central nervous system depressants: additive sedation and respiratory depression. - Serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - Alcohol: enhances CNS depressive effects.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce mirtazapine efficacy. - Anticholinergic drugs: combined anticholinergic burden may increase side effects.